NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.
Sarah P. Blagden(Churchill Hospital), Jordan Berlin(Dana-Farber Cancer Institute), Essam Ghazaly(Queen Mary University of London), T.R. Jeffry Evans(University of Glasgow), Aimery de Gramont(Institut Hospitalier Franco Britannique), Josep Tabernero(Deaconess Hospital), Chathunissa Gnanaranjan(Queen Mary University of London)
Cited by 1
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Genomic analysis identifies association of <i>Fusobacterium</i> with colorectal carcinoma
|Genome Research|2011|2k